Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27425945 | 1.00 | LPAR1 (0.44) | LPAR1LPAR3ALDH1A1LMNATLR2 | |
| SCHEMBL27425949 | 1.00 | LPAR1 (0.44) | LPAR1LPAR3ALDH1A1LMNATLR2 | |
| SCHEMBL27425944 | 1.00 | LPAR1 (0.44) | LPAR1LPAR3ALDH1A1LMNATLR2 | |
| SCHEMBL27425964 | 0.86 | DNM1 (0.43) | — | |
| SCHEMBL27425959 | 0.86 | DNM1 (0.43) | — | |
| SCHEMBL27425957 | 0.86 | DNM1 (0.43) | — | |
| SCHEMBL27425953 | 0.86 | DNM1 (0.43) | — | |
| SCHEMBL27425962 | 0.86 | DNM1 (0.43) | — | |
| SCHEMBL27425920 | 0.85 | LPAR1 (0.53) | LPAR1LPAR3ALDH1A1LMNATLR2 | |
| SCHEMBL27425931 | 0.85 | LPAR1 (0.53) | LPAR1LPAR3ALDH1A1LMNATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | LPAR1 119/4885LPAR3 140/4885ALDH1A1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.